- Agata Mertyn Within TREAT-NMD Agata is responsible for leading the work around TREAT NMD communications and global...
TACT is pleased to announce the following applications will be reviewed at the TACT meeting scheduled for 27 – 28 April, Baltimore, MD, USA:
- Peter Flynn, Fate Therapeutics Inc, San Diego, CA, USA: Wnt7a-Analog Protein Therapeutic for the Treatment of Muscular Dystrophy
- Jon Tinsley, Summit Corporation plc, Abingdon, UK: Clinical development of SMT C1100, a utrophin modulator for the treatment of Duchenne muscular dystrophy
According to the process TACT will generate a detailed report with program development recommendations to the applicant within 6 weeks following the meeting. A non‐confidential report summary, developed in collaboration with the applicant, will be available in this section of the website within 8 weeks following the meeting.
Dates for the subsequent TACT meeting are soon to be confirmed and individuals interested in potentially submitting an application should send an expression of interest to the TACT secretariat Agata Mertyn as soon as possible.